Sifalimumab
Based on 1 Customer Validation
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.46%
- CAS. Nr.: 1006877-41-3
- Molecular Weight:144.24 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG1 kappa
Human
IFNA1
Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U-87MG cells and AGS lymphocytes
-
Concentration:3-36 μg/well
-
Incubation Time:72 hours
-
Result:Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wild-type male BALB/c mice[2]
-
Dosage:30 mg/kg and 3 μg/g
-
Administration:Subcutaneous injection; 30 mg/kg and 3 μg/g
-
Result:Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05).
Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration.
Attenuated the CD45 increase (P<0.05).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IFN-alpha 1/IFNA13 Protein, Human (HEK293, His, HY-P70241) can bind Sifalimumab. The EC50 for this effect is 1.843 ng/mL.
Chemical Information
-
CAS. Nr. 1006877-41-3
-
Appearance Liquid
-
Molecular Weight 144.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Sifalimumab]
-
Synonyms
MEDI-545; MDX 1103
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13. [Content Brief]
[2]. La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8(5):1345-1354. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Sifalimumab Related Classifications
HY-P99219 Related Classifications
Powered by Bioz